Head to head
Halozyme Therapeutics vs Vertex Pharmaceuticals
Side-by-side on the measures that matter, with a plain-English read. Full detail: HALO · VRTX
HALO
Halozyme Therapeutics
91.35-1.82%
1-year price shape — +32% over the period
Quant Rating C · 75/100
vs
VRTX
Vertex Pharmaceuticals
515.02-1.08%
1-year price shape — +22% over the period
Quant Rating C · 68/100
1-year performance, rebased to 100
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals earns the most per share.
| HALO | VRTX | |
|---|---|---|
| Snapshot | ||
| Sector | Biotechnology | Biotechnology |
| Last price | 91.35 | 515.02 |
| Change today | -1.82% | -1.08% |
| 1-year return | +32.4% | +22.0% |
| Market cap | $10.41B | $130.58B |
| 52-week range | 61.23 – 134.00 | 412.27 – 568.67 |
| Valuation | ||
| P/E (TTM) | 22.84 | 33.14 |
| P/E percentile, own 5-yr range | 65th | 99th |
| P/B | -188.35 | 6.25 |
| Dividend yield | 0.00% | 0.00% |
| Profitability & growth | ||
| EPS (TTM) | 2.56 | 15.32 |
| Net profit (TTM) | $291.87M | $3.88B |
| Revenue (TTM) | $1.80B | $12.95B |
| Provider revenue period date | 2026-09-29 | 2026-09-29 |
| Revenue growth (YoY) | +39.2% | +11.8% |
| Gross margin | 82.3% | 85.5% |
| Operating margin | 55.9% | 33.1% |
| Net margin | 26.9% | 30.7% |
| Free cash flow (TTM) | $598.10M | $3.20B |
| Provider cash-flow period date | 2026-09-29 | 2026-09-29 |
| Ownership & sentiment | ||
| Institutional ownership | 114.0% | 96.8% |
| Insider activity (12mo) | 26 buy / 24 sell | 28 buy / 22 sell |
| Short interest (% of float) | 12.0% | 1.9% |
| Analyst consensus | 80% buy / 20% hold (5) | 95% buy / 5% hold (21) |
| Analyst price target | $126 (+37%) | $624 (+21%) |
| StockVane view | ||
| StockVane Quant Rating | C (75) | C (68) |
| Company | ||
| Employees | 423 | 6,400 |
| Founded | 1998 | 1989 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.